Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sinovac Releases Positive Update on A/H1N1 Flu Vaccine Trial

publication date: Aug 3, 2009

Sinovac Biotech (北京科兴生物制品有限公司) released an early report from the clinical trial of its A/H1N1 influenza vaccine, announcing that no severe adverse reactions were observed following the first inoculation. Participants experienced an 11.8% rate of adverse reactions. That is approximately equal to the average vaccine reaction and consisted mainly of pain at the injection site. More details...

Stock Symbol: (NYSE AMEX: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital